0001193125-26-054509
SEC filingNeuphoria Therapeutics Inc. reported a net income of $1.9 million for Q2 2025, a significant improvement from an operating loss of $4.1 million, driven primarily by a $5.4 million gain on fair value adjustments. Total revenue was limited to $663K from license agreements. The company's operating expenses totaled $4.1 million, consisting of $698K in research and development, $2.1 million in general and administrative costs, and $1.2 million in restructuring costs. Cash flow from operations was negative at -$7.8 million, but financing activities provided $17.9 million from equity sales, resulting in a net cash increase of $8.0 million. The balance sheet shows strong liquidity with $22.2 million in cash and equivalents and total assets of $36.6 million against liabilities of $6.9 million.
Neuphoria Therapeutics reported Q2 2025 results with net income of $1.9 million, a positive outcome despite an operating loss of $4.1 million. The company generated $663K in license revenue while incurring $4.1 million in operating expenses ($698K R&D, $2.1M G&A, $1.2M restructuring). The turnaround to profitability was primarily due to a $5.4 million gain on fair value adjustments, which contributed to total other income of $5.9 million. Other income components included $167K interest income, -$136K foreign currency loss, and -$479K R&D incentive award. The company reported comprehensive income of $2.4 million including $571K unrealized foreign currency gain. Basic EPS was $0 with 4.5 million weighted-average shares outstanding.
Revenue for the quarter consisted entirely of $663K from license agreements. No segment breakdown or geographic revenue mix was disclosed in the provided data. The company's revenue stream appears limited to licensing activities during this period, with no product sales or other revenue sources mentioned. The license revenue represents the company's primary income generation mechanism outside of investment activities and fair value adjustments.
The company operated at a significant operating loss margin due to minimal revenue relative to expenses. With $663K revenue and $4.1M operating expenses, the operating loss was -$4.1 million. Profitability was achieved only through substantial non-operating gains, particularly the $5.4 million gain on fair value adjustments. The cost structure shows higher general and administrative expenses ($2.1M) compared to research and development ($698K), with additional restructuring costs of $1.2 million impacting the quarter's results.
Operating activities used $7.8 million in cash, primarily due to the net income of $1.9M being offset by various non-cash adjustments and working capital changes. Key adjustments included $205K share-based compensation, $332K depreciation/amortization, and -$989K change in fair value of warrant liability. Financing activities provided $17.9 million from equity sales net of issuance costs. The balance sheet shows strong liquidity with $22.2M cash and equivalents, total current assets of $23.4M, and total assets of $36.6M. Liabilities total $6.9M including $2.7M warrant liability and $1.2M contingent consideration. Shareholders' equity stands at $29.7M with accumulated deficit of -$186.4M.
No specific forward-looking guidance, strategic priorities, or risk factors were provided in the data. The filing contains standard financial statements without management discussion of future expectations. Investors should note the company's reliance on non-operating gains for profitability and the significant cash burn from operations (-$7.8M), though this was offset by substantial equity financing ($17.9M). The balance sheet indicates adequate liquidity for near-term operations with $22.2M in cash.